Etoposide 100 mg/m^2

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Non-small Cell Lung CancerSmall Cell Lung CancerSolid Tumor

Phase 1

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

CompletedNCT01840579

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumor

Start: 2013-04-26End: 2020-02-28Updated: 2021-06-22

Phase 3

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Active, not recruitingNCT04624204

Merck Sharp & Dohme LLCSmall Cell Lung Cancer

Start: 2020-12-08End: 2027-10-28Target: 672Updated: 2025-07-02

Related Papers

A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancer.

2025-03-03

Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.

2024-02-01

Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.

2022-04-2911 citations

Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs. Concurrent Chemoradiation Therapy in Patients With Newly Diagnosed Limited-Stage Small-Cell Lung Cancer: KEYLYNK-013.

2021-11-01

Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC.

2021-09-153 citations

KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.

Journal of Clinical Oncology2021-05-204 citations